Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCD-R for PTLD in Children
NCT01088724Phase 4Completed
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Feb 2002
- Primary completion
- Mar 2010
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of fludarabine, cyclophosphamide, doxorubicin, rituximab in Post-transplant lymphoproliferative disease (PTLD), sponsored by Papa Giovanni XXIII Hospital. Started Feb 2002; status: completed.
02
Drugs
fludarabinecyclophosphamidedoxorubicinrituximab
03
Conditions
Post-transplant lymphoproliferative disease (PTLD)
Beyond the preview
Go deeper on NCT01088724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01088724.